A 28-year-old man with type 1 diabetes mellitus presents to the hospital with diabetic ketoacidosis (DKA). His blood glucose is 420 mg/dL, arterial pH is 7.18, serum bicarbonate is 8 mEq/L, and serum ketones are markedly elevated. Despite hyperglycemia, his liver is actively synthesizing glucose via gluconeogenesis. Which of the following best explains why gluconeogenesis continues unabated in the presence of high blood glucose in DKA?

Explanation

## Gluconeogenesis in Diabetic Ketoacidosis (DKA) ### Pathophysiology of DKA In type 1 diabetes with DKA, there is **absolute insulin deficiency** and **relative or absolute glucagon excess**. This creates a metabolic paradox: despite severe hyperglycemia (420 mg/dL), the liver continues to produce glucose at an accelerated rate, worsening hyperglycemia and osmotic stress. ### The Glucagon-Driven Gluconeogenesis Paradox **Key Point:** In DKA, gluconeogenesis is driven by **elevated glucagon**, which acts independently of blood glucose levels. Normally, high blood glucose suppresses glucagon secretion via feedback inhibition. However, in insulin deficiency, this feedback loop is broken — glucagon remains elevated despite high glucose. **High-Yield:** Glucagon activates gluconeogenesis through two mechanisms: 1. **Acute effects**: Phosphorylation of PFK-2/FBPase-2 → ↓ F2,6BP → ↓ glycolysis, ↑ gluconeogenesis 2. **Chronic effects**: Upregulation of PEPCK (phosphoenolpyruvate carboxykinase) gene expression via cAMP-PKA-CREB pathway ### Why Glucose Does NOT Suppress Gluconeogenesis in DKA ```mermaid flowchart TD A[Type 1 Diabetes<br/>Absolute Insulin Deficiency]:::urgent --> B[Glucagon NOT suppressed<br/>by high glucose]:::action B --> C[Elevated Glucagon<br/>acts on hepatocytes]:::outcome C --> D[Activates cAMP-PKA pathway]:::action D --> E[PEPCK gene upregulation]:::action E --> F[Gluconeogenesis continues<br/>DESPITE high blood glucose]:::urgent G[Normal state:<br/>High glucose → Insulin ↑<br/>Glucagon ↓]:::outcome G -->|BROKEN in DKA| H[Insulin cannot suppress<br/>gluconeogenesis]:::urgent ``` ### Mechanism: Glucagon-Independent Gluconeogenesis **Mnemonic: PEPCK-UP = Glucagon Pumps Up PEPCK** | Factor | Normal Fasting | DKA | |--------|---|---| | **Blood Glucose** | 80–100 mg/dL | 300–600 mg/dL | | **Insulin** | Low but present | Absent | | **Glucagon** | Moderately elevated | **Markedly elevated** | | **Glucose feedback on glucagon** | Suppresses glucagon | **ABSENT** | | **PEPCK expression** | Baseline ↑ | **Markedly ↑↑** | | **Gluconeogenesis rate** | ~2 μmol/kg/min | **~4–6 μmol/kg/min** | | **Net glucose output** | Matches glucose utilization | **EXCEEDS utilization** | ### Why Insulin Deficiency Is the Root Cause Insulin normally suppresses gluconeogenesis through multiple pathways: 1. **Inhibits glucagon secretion** (α-cell feedback) 2. **Activates PFK-2** → ↑ F2,6BP → inhibits FBPase-1 → blocks gluconeogenesis 3. **Activates protein phosphatase-1** → dephosphorylates and inactivates gluconeogenic enzymes 4. **Reduces substrate availability** (↓ lipolysis → ↓ glycerol; ↓ proteolysis → ↓ alanine) In DKA, **all of these inhibitory pathways are absent**, allowing glucagon to drive gluconeogenesis unchecked. ### Clinical Pearl This is why **insulin therapy is the cornerstone of DKA treatment**, not just glucose-lowering: insulin suppresses both ketogenesis (via ↓ lipolysis) and gluconeogenesis (via ↓ glucagon and direct hepatic effects). Merely lowering blood glucose with fluids or insulin without addressing the underlying insulin deficiency would not stop hepatic glucose production. [cite:Harrison 21e Ch 397; Lehninger Principles of Biochemistry 7e Ch 20]